BerGenBio

$BGBIO We are a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL in aggressive diseases

[BerGenBio @BGenBio]

Our CEO, Martin Olin, comments on today’s Q1 2022 results.

You can read the report in full here: https://t.co/PvHkfNjldt

#FinancialResults #BGBIO

[BerGenBio @BGenBio]

Today we announced our Q1 2022 results. A presentation by BerGenBio’s senior management team will take place today at 10 am CEST - watch the webcast here: https://t.co/K99HU4OXYv

Read the full PR here: https://t.co/bgjzwXue9E

#FinancialResults

[BerGenBio @BGenBio]

We’re pleased to announce complete data analysis from the #ACCORD2 phase II study of #bemcentinib in combination with #SoC therapy in hospitalized #COVID19 patients. The primary endpoint of improved clinical response was met.

Read the full release here: https://t.co/04cC286blX

[BerGenBio @BGenBio]

The data presented at #ECCMID2022 today demonstrate that bemcentinib treatment provides early and sustained protection, limiting clinical deterioration in moderate to severe #COVID19 patients.

Read the full release here: https://t.co/s53zW1Uhj5

#BGBIO #oncology #Presenation

[BerGenBio @BGenBio]

We’re presenting data from our BGBC020 clinical trial in hospitalised #COVID19 patients today at #ECCMID2022.

Read the full release here: https://t.co/hrgSETB2YP

[BerGenBio @BGenBio]

Yesterday we announced a publication in Cell Reports Medicine on #AXL as a driver of immune suppression in STK11/LKB1 mutated NSCLC.

STK11 is associated with poor treatment outcomes in NSCLC. There are currently no STK11-targeted therapies .

Link: https://t.co/YVGIWY8bp0

[BerGenBio @BGenBio]

BerGenBio’s CEO, Martin Olin, comments on today’s Q4 and FY 2021 results.

You can view the report in full here: https://t.co/7GEPlRhwbR

#financialresults #BGBIO

[BerGenBio @BGenBio]

Today we announced our Q4 and FY 2021 #results. A presentation by BerGenBio’s senior management team will take place today at 10am CET. If you would like to watch the live webcast, follow this link: https://t.co/05YdaQCmWE

Read the press release here: https://t.co/lL6C8DnjB6

[BerGenBio @BGenBio]

We’re pleased to announce that our lead candidate, #bemcentinib, has been selected for inclusion in a pan-European research project exploring potential treatments for hospitalised COVID-19 patients, the @EU_SolidAct trial.

Read the release here: https://t.co/mhL7gabBdp

#AXL

[BerGenBio @BGenBio]

This morning BerGenBio announced a license agreement with @UTSWNews

The exclusive license is related to the treatment of Non-Small Cell Cancer (NSCLC) patients with #STK11 mutations and supports the Company’s existing IP position.

Read here: https://t.co/SOcFdp7L8o

[BerGenBio @BGenBio]

CEO Martin Olin comments on BerGenBio’s Q3 2021 results, out today.

You can view the report in full here: https://t.co/fNbBUwsXP5

#financialresults #BGBIO

[BerGenBio @BGenBio]

We are pleased to announce our Q3 2021 results. A presentation by BerGenBio’s senior management team will take place today at 10am CET.

For the full webcast: https://t.co/RMGIppbzxE

For the full PR: https://t.co/9ziokkl3ha

#oncology #financialresults #BGBIO

[BerGenBio @BGenBio]

Register to watch BerGenBio's Satellite Symposium taking place today at the EHA SWG at 17:30 CET here: https://t.co/gClnQUENkL

#EHA #hematology

[BerGenBio @BGenBio]

September is Blood Cancer Awareness Month. Blood cancer affects millions and BerGenBio shares the vision of raising awareness and understanding of blood cancers, including #AML, the most common form of acute leukaemia.

Learn more here: https://t.co/N6DCv4MLRb

#BCAM2021

[BerGenBio @BGenBio]

Today we announced our financial results for the second quarter and first half of 2021.

A presentation by BerGenBio's senior management team will take place today at 10:00 am CET at this link: https://t.co/wGlTe3MQA3

Read the full announcement here: https://t.co/RGPeTcPTJk

[BerGenBio @BGenBio]

Yesterday we were honoured to host @IselinNybo the Norwegian Minister of Trade and Industry, at BerGenBio - see some pictures from the visit below. #Norway #NorweiganBiotech #BGBIO

[BerGenBio @BGenBio]

In case you missed it, our CEO Richard Godfrey commented on our exciting progress last week in this video – watch it on our website here: https://t.co/cJEs864Cz3 #CEOVideo #EHA #ECCMID #oncology

[BerGenBio @BGenBio]

Our CEO, Richard Godfrey, comments on a very exciting and encouraging week for #BerGenBio. To learn more about the progress we’ve made this week and our outlook, watch the video here: https://t.co/cJEs864Cz3

#bemcentinib #oncology #immunooncology

[BerGenBio @BGenBio]

Today we are pleased to be presenting preliminary data at the EHA Virtual Meeting, showing that #bemcentinib in combination with LDAC has shown encouraging preliminary updated survival data in our Phase II study in relapsed #AML patients. Read more here: https://t.co/nR3OcfZcFW

[BerGenBio @BGenBio]

Want to hear more about BerGenBio’s latest COVID-19 updates? Have a read of this in-depth piece from Cormac Sheridan at BioWorld, featuring commentary from CEO Richard Godfrey.

https://t.co/tgTNhyYYNP

#bemcentinib #COVID19